In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections.

Abstract

BAY Y3118 was highly active against Moraxella catarrhalis, Haemophilus influenzae, Legionella pneumophila, Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus (except quinolone-resistant, methicillin-resistant S. aureus), Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus agalactiae, and Streptococcus pneumoniae (MIC for 90% of strains tested [MIC90], 0.063 micrograms/ml). For Enterococcus faecalis and Corynebacterium jeikeium, MIC90s were 4 and 2 micrograms/ml, respectively. BAY Y3118 was as active as ciprofloxacin against Pseudomonas aeruginosa (MIC90, 0.5 micrograms/ml) and had potent activity against Bacteroides fragilis (MIC90, 0.5 micrograms/ml).

• Authors: G P Bongaerts, J A Hoogkamp-Korstanje
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 37 Issue 9 Pg. 2017-9 (Sep 1993) ISSN: 0066-4804 [Print] United States
• PMID: 8239624 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Infective Agents
• Fluoroquinolones
• Quinolones
• Bay Y3118

Topics

• Anti-Infective Agents (pharmacology)
• Fluoroquinolones
• Gram-Negative Bacteria (drug effects)
• Gram-Negative Bacterial Infections (microbiology)
• Gram-Positive Bacteria (drug effects)
• Gram-Positive Bacterial Infections (microbiology)
• Humans
• Microbial Sensitivity Tests
• Quinolones (pharmacology)
• Respiratory Tract Infections (microbiology)